GlobeNewswire: Tetraphase Pharmaceuticals, Inc. Contains the last 10 of 107 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T19:48:09ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/12/05/1662291/0/en/Tetraphase-Pharmaceuticals-to-Present-at-BMO-Prescriptions-for-Success-Healthcare-Conference.html?f=22&fvtc=4&fvtv=24851Tetraphase Pharmaceuticals to Present at BMO Prescriptions for Success Healthcare Conference2018-12-05T11:30:00Z<![CDATA[WATERTOWN, Mass., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that President and Chief Executive Officer Guy Macdonald will present a corporate overview at the BMO Prescriptions for Success Healthcare Conference on Wednesday, December 12, 2018 at 9:40 a.m. ET at the Mandarin Oriental Hotel in New York City.]]>https://www.globenewswire.com/news-release/2018/11/08/1648481/0/en/Tetraphase-Pharmaceuticals-Reports-Third-Quarter-2018-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=24851Tetraphase Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update2018-11-08T21:01:00Z<![CDATA[XERAVATM (eravacycline) Now Available to Hospitals in the United States]]>https://www.globenewswire.com/news-release/2018/11/07/1646752/0/en/Tetraphase-Pharmaceuticals-to-Present-at-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=24851Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences2018-11-07T11:00:00Z<![CDATA[WATERTOWN, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that President and Chief Executive Officer Guy Macdonald will present a corporate overview at the Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018 at 8:00 a.m. ET at Lotte New York Palace Hotel in New York City. Mr. Macdonald also will participate in a fireside chat at the Piper Jaffray 30th Annual Healthcare Conference on Tuesday, November 27, 2018 at 2:30 p.m. ET at the Lotte New York Palace Hotel in New York City.]]>https://www.globenewswire.com/news-release/2018/11/01/1641599/0/en/Tetraphase-Pharmaceuticals-to-Host-Third-Quarter-2018-Financial-Results-Conference-Call.html?f=22&fvtc=4&fvtv=24851Tetraphase Pharmaceuticals to Host Third Quarter 2018 Financial Results Conference Call2018-11-01T20:01:00Z<![CDATA[WATERTOWN, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will host a conference call at 4:30 p.m. ET on Thursday, November 8, 2018 to discuss third quarter financial results and provide a general corporate update.]]>https://www.globenewswire.com/news-release/2018/10/23/1625230/0/en/Tetraphase-Pharmaceuticals-Announces-Positive-Data-from-Post-Hoc-Analysis-of-Phase-3-Trials-Demonstrating-Efficacy-of-XERAVA-eravacycline-in-Obese-and-Renally-Impaired-Patients-wit.html?f=22&fvtc=4&fvtv=24851Tetraphase Pharmaceuticals Announces Positive Data from Post-Hoc Analysis of Phase 3 Trials Demonstrating Efficacy of XERAVA™ (eravacycline) in Obese and Renally Impaired Patients with Complicated Intra-Abdominal Infections2018-10-23T10:30:00Z<![CDATA[WATERTOWN, Mass., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, announced data from two post-hoc analyses of pooled data from two Phase 3 IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline) studies of XERAVA in patients with complicated intra-abdominal infections (cIAI). These data were presented at the 2018 American College of Clinical Pharmacy (ACCP) Global Conference on Clinical Pharmacy, held October 20-23 in Seattle, WA.]]>https://www.globenewswire.com/news-release/2018/10/11/1620275/0/en/Tetraphase-Pharmaceuticals-Announces-Commercial-Launch-of-XERAVA-in-the-United-States.html?f=22&fvtc=4&fvtv=24851Tetraphase Pharmaceuticals Announces Commercial Launch of XERAVA™ in the United States2018-10-11T20:01:00Z<![CDATA[FDA-Approved for the Treatment of Complicated Intra-Abdominal Infections]]>https://www.globenewswire.com/news-release/2018/10/08/1617839/0/en/Tetraphase-Pharmaceuticals-Announces-Presentation-of-Positive-Data-from-Phase-3-Trials-of-XERAVA-eravacycline-and-Multiple-Ascending-Dose-Trial-of-TP-6076-at-IDWeek-2018.html?f=22&fvtc=4&fvtv=24851Tetraphase Pharmaceuticals Announces Presentation of Positive Data from Phase 3 Trials of XERAVA™ (eravacycline) and Multiple-Ascending Dose Trial of TP-6076 at IDWeek 20182018-10-08T10:30:00Z<![CDATA[XERAVA Demonstrated Efficacy in Treating Secondary Bacteremia in Patients with Complicated Intra-Abdominal Infections in Post-Hoc Analysis of Phase 3 Clinical Trials]]>https://www.globenewswire.com/news-release/2018/09/28/1587111/0/en/Tetraphase-Pharmaceuticals-Announces-Inducement-Grants-under-NASDAQ-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=24851Tetraphase Pharmaceuticals Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)2018-09-28T20:01:00Z<![CDATA[WATERTOWN, Mass., Sept. 28, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that Tetraphase's Compensation Committee of the Board of Directors approved, pursuant to NASDAQ Listing Rule 5635(c)(4), the grant of inducement equity awards in the form of stock options to over thirty new sales employees to purchase an aggregate of 128,250 shares of Tetraphase's common stock. The options were granted as inducement equity awards outside Tetraphase's 2013 Stock Incentive Plan and were made as an inducement material to these new employees’ acceptance of employment with Tetraphase.]]>https://www.globenewswire.com/news-release/2018/09/24/1575275/0/en/Tetraphase-Pharmaceuticals-to-Present-at-the-Cantor-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=24851Tetraphase Pharmaceuticals to Present at the Cantor Global Healthcare Conference2018-09-24T20:01:00Z<![CDATA[WATERTOWN, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that President and Chief Executive Officer Guy Macdonald will present a corporate overview at the Cantor Global Healthcare Conference on Monday, October 1, 2018 at 5:15 p.m. Eastern Time at InterContinental New York Barclay Hotel in New York City.]]>https://www.globenewswire.com/news-release/2018/09/20/1573982/0/en/Tetraphase-Pharmaceuticals-Announces-Adoption-of-Commission-Decision-Granting-Marketing-Authorisation-Approval-in-the-European-Union-for-XERAVA-eravacycline-for-the-Treatment-of-Co.html?f=22&fvtc=4&fvtv=24851Tetraphase Pharmaceuticals Announces Adoption of Commission Decision Granting Marketing Authorisation Approval in the European Union for XERAVA™ (eravacycline) for the Treatment of Complicated Intra-Abdominal Infections2018-09-20T17:08:57Z<![CDATA[– Broad Product Label for Treatment of Complicated Intra-Abdominal Infections –]]>